胶质母细胞瘤（GBM）是一种恶性癌症，即使进行标准治疗也具有致命性，目前可用治疗的效果并不理想，这是由于其复杂且日益演化的表观遗传和遗传特征。导致GBM肿瘤内异质性和亚型转化的奥秘不完全清楚。系统医学是一种将系统生物学和合成生物学与计算技术融合的方法，以整体视角看待患者。由于GBM的肿瘤发生涉及基因突变，因此本文讨论并提出基于CRISPR-Cas技术、微小RNA和植入合成细胞等各种治疗方法，其中神经干细胞和间充质干细胞作为潜在载体通过经鼻途径携带治疗方法，避免侵入性方法的风险，以达到抵抗GBM的优良效果。系统医学方法是一种相当新颖的策略，由于患者的GBM很复杂且独特，因此根据系统医学概念为个体患者量身定制个性化多模式治疗策略，考虑GBM表型、患者独特的身体健康状况和个体反应，可能表现出潜在的最佳效果。© 2023. 作者（或授权人）独家授权给斯普林格科学+商业媒体有限责任公司，斯普林格自然出版集团的一部分。

Glioblastoma (GBM) is a malignant cancer that is fatal even after standard therapy and the effects of current available therapeutics are not promising due its complex and evolving epigenetic and genetic profile. The mysteries that lead to GBM intratumoral heterogeneity and subtype transitions are not entirely clear. Systems medicine is an approach to view the patient in a whole picture integrating systems biology and synthetic biology along with computational techniques. Since the GBM oncogenesis involves genetic mutations, various therapies including gene therapeutics based on CRISPR-Cas technique, MicroRNAs, and implanted synthetic cells endowed with synthetic circuits against GBM with neural stem cells and mesenchymal stem cells acting as potential vehicles carrying therapeutics via the intranasal route, avoiding the risks of invasive methods in order to reach the GBM cells in the brain are discussed and proposed in this review. Systems medicine approach is a rather novel strategy, and since the GBM of a patient is complex and unique, thus to devise an individualized treatment strategy to tailor personalized multimodal treatments for the individual patient taking into account the phenotype of the GBM, the unique body health profile of the patient and individual responses according to the systems medicine concept might show potential to achieve optimum effects.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.